Stage (next event)
Phase 2 Readout
Catalyst Info & Data Links
TITLE: NYX-2925 for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy Phase 2 Readout
Clinical Trial (NCT04146896) Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)
WHAT IS THE NEXT CATALYST EVENT?
Phase 2 to be initiated
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Mechanism of Action
MECHANISM OF ACTION
NMDA receptors are critically important in normal brain and nervous system function and play a key role in regulating how neurons connect to each other. The activation and opening of NMDA receptors, in response to the binding of specific neurotransmitters including glutamate, triggers a cascade of events that results in synaptic plasticity. This activation may be a beneficial therapeutic approach to treating disorders of the brain and nervous system.
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post